PATENT CLAIM ANALYSIS

Application Number: 15927032
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "133100"]

Abstract:
Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.

Claim (Index 9):
The method of  claim 7 , which induces a clinical response or clinical remission of ulcerative colitis in the human patient.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 90.0
- Lexical Diversity: 1.26667
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15215000', '15214993', '15215012', '14114832', '14114835']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8343424986751435
- 35 USC 102 Novelty (BERT): 0.6160508419894456
- Combined Prediction Score: 0.8125133330065737
- Mean Citation Score: 638.1288179999998
- Max Citation Score: 683.86127
- Similarity Product: 484.71476617557227

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test